The Goldman Sachs Group Issues Pessimistic Forecast for Beta Bionics (NASDAQ:BBNX) Stock Price

Beta Bionics (NASDAQ:BBNX) had its price objective lowered by research analysts at The Goldman Sachs Group from $23.00 to $20.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 125.73% from the company’s current price.

BBNX has been the subject of several other research reports. Bank of America lowered shares of Beta Bionics from a “buy” rating to a “neutral” rating in a report on Friday, January 9th. UBS Group upgraded shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. Wall Street Zen lowered shares of Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Robert W. Baird lowered their target price on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Finally, Stifel Nicolaus decreased their price objective on shares of Beta Bionics from $25.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.70.

Beta Bionics Stock Down 8.0%

Shares of NASDAQ:BBNX opened at $8.86 on Thursday. Beta Bionics has a 52 week low of $8.80 and a 52 week high of $32.71. The stock has a market capitalization of $393.21 million, a P/E ratio of -4.54 and a beta of 5.06. The firm has a fifty day simple moving average of $11.82 and a two-hundred day simple moving average of $20.42.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. The business had revenue of $32.12 million during the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Institutional Trading of Beta Bionics

Several large investors have recently bought and sold shares of BBNX. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Beta Bionics by 140.9% in the 4th quarter. Invesco Ltd. now owns 117,360 shares of the company’s stock valued at $3,576,000 after acquiring an additional 68,640 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Beta Bionics in the 4th quarter valued at $1,340,000. Voloridge Investment Management LLC boosted its holdings in shares of Beta Bionics by 549.6% in the 4th quarter. Voloridge Investment Management LLC now owns 151,647 shares of the company’s stock valued at $4,621,000 after acquiring an additional 128,301 shares during the last quarter. Finally, Tudor Investment Corp ET AL boosted its holdings in shares of Beta Bionics by 572.7% in the 4th quarter. Tudor Investment Corp ET AL now owns 259,632 shares of the company’s stock valued at $7,911,000 after acquiring an additional 221,039 shares during the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.